Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD
Add to favourite- Summary
- Historical Data
| Spread | 44.6 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.011247% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.010976% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | JPY | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Japan | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5972.3 |
| Open | 6195.7 |
| 1-Year Change | 55.76% |
| Day's Range | 6195.7 - 6362.6 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 26, 2024 | 6283.6 | 74.9 | 1.21% | 6208.7 | 6378.4 | 6174.8 |
| Jul 25, 2024 | 5988.2 | -136.7 | -2.23% | 6124.9 | 6173.8 | 5959.3 |
| Jul 24, 2024 | 6134.0 | 169.5 | 2.84% | 5964.5 | 6193.8 | 5948.3 |
| Jul 23, 2024 | 5996.1 | 90.4 | 1.53% | 5905.7 | 6029.4 | 5905.7 |
| Jul 22, 2024 | 5913.5 | -29.6 | -0.50% | 5943.1 | 5980.0 | 5869.3 |
| Jul 19, 2024 | 5881.3 | 0.9 | 0.02% | 5880.4 | 5904.1 | 5785.6 |
| Jul 18, 2024 | 5965.4 | 31.2 | 0.53% | 5934.2 | 6016.6 | 5835.5 |
| Jul 17, 2024 | 6049.1 | -21.0 | -0.35% | 6070.1 | 6097.7 | 6008.9 |
| Jul 16, 2024 | 6043.9 | -123.6 | -2.00% | 6167.5 | 6201.0 | 6043.9 |
| Jul 12, 2024 | 6274.6 | 33.0 | 0.53% | 6241.6 | 6350.3 | 6220.6 |
| Jul 11, 2024 | 6333.3 | -52.8 | -0.83% | 6386.1 | 6393.8 | 6297.5 |
| Jul 10, 2024 | 6377.2 | 134.6 | 2.16% | 6242.6 | 6405.3 | 6242.6 |
| Jul 9, 2024 | 6295.5 | 180.2 | 2.95% | 6115.3 | 6304.0 | 6089.1 |
| Jul 8, 2024 | 6175.9 | 20.0 | 0.32% | 6155.9 | 6340.8 | 6139.0 |
| Jul 5, 2024 | 6152.0 | 31.9 | 0.52% | 6120.1 | 6191.9 | 6108.1 |
| Jul 4, 2024 | 6082.1 | 38.9 | 0.64% | 6043.2 | 6109.0 | 5970.3 |
| Jul 3, 2024 | 5967.4 | 114.2 | 1.95% | 5853.2 | 6005.6 | 5824.1 |
| Jul 2, 2024 | 5767.9 | 155.2 | 2.77% | 5612.7 | 5812.4 | 5612.7 |
| Jul 1, 2024 | 5637.2 | 22.5 | 0.40% | 5614.7 | 5662.2 | 5527.9 |
| Jun 28, 2024 | 5680.1 | -109.0 | -1.88% | 5789.1 | 5808.1 | 5650.5 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Chugai Pharmaceutical Co., Ltd. Company profile
About Chugai Pharmaceutical Co Ltd
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chugai Pharmaceutical Co Ltd revenues increased 27% to Y999.76B. Net income increased 41% to Y303B. Revenues reflect Net Sales increase of 27% to Y802.84B, Royalties and other operating revenues increase of 28% to Y196.92B. Dividend per share increased from Y55.00 to Y76.00. Basic Earnings per Share excluding Extraordinary Items increased from Y130.66 to Y184.29.
Equity composition
FY'03, the Co. changed FY end from March to December. FY'94-'02 WAS & FY'04 Q1 &Q3 WAs & O/S were estimated. 3/05 & 9/05, WAS, O/S, DPS were estimated. FY'06 Q3 & '07 Q1, Q3 WAS& DWAS were estimated, and its WAS was used as O/S. FY'08 1Q WAS & DWAS were estimated and WAS was used as o/s. FY'08 Q3 WAS estimated and used as o/s.
| Industry: | Pharmaceuticals (NEC) |
日本橋三井タワー15f
日本橋室町2-1-1
CHUO-KU
TOKYO-TO 103-8324
JP
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com